Key result
Catheter ablation significantly improves symptoms and quality of life in patients with atrial fibrillation, though evidence for reducing hard clinical endpoints is currently limited to patients with heart failure.
Catheter ablation is an established and effective treatment for atrial fibrillation that significantly improves symptoms and quality of life, with emerging evidence of hard clinical endpoint benefits specifically in patients with heart failure.
Answers are grounded in this paper and cite their sources.
Supports ablation for symptom control in AF; leaves open hard-endpoint benefits beyond heart failure.
Atrial fibrillation (AF) is the most common human arrhythmia. Interventional treatment with catheter ablation is an established technique that is increasingly applied and has become one of the main treatment modalities in patients with AF. Ablation results in significant improvement of symptoms and the quality of life. There is as yet no clear evidence of any impact of the procedure on hard clinical endpoints, except in patients with heart failure, who seem to benefit significantly from ablation. The cornerstone of the procedure is the achievement of pulmonary vein isolation. Radiofrequency energy is the main applied energy source, but cryoballoon ablation has emerged as a safe and effective alternative to radiofrequency ablation. Additional ablation strategies and novel technical features have been proposed but without unequivocal proof of clinical benefit. The most promising of these seems to be substrate mapping of the left atrium with substrate modification in areas with low voltage as an adjunct to pulmonary vein isolation. Complication rates remain considerable despite accumulated experience and can be partly reduced by application of preventive measures.
No takes yet. Share an insight, caveat, or question.
Hindricks et al. (2018) conducted a review in Atrial fibrillation. Catheter ablation vs. Medical treatment was evaluated. Catheter ablation significantly improves symptoms and quality of life in patients with atrial fibrillation, though evidence for reducing hard clinical endpoints is currently limited to patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: